for the treatment of common meningeal pathogens ( streptococcus pneumoniae , haemophilus influenzae , and neisseria meningitidis ) and for gram-negative bacilli , mainly escherichia coli and klebsiella ( excluding pseudomonas aeruginosa ) , the cefotaxime-ceftriaxone group of cephalosporins has accrued the most clinical experience and the most pharmacokinetic data , while for p. aeruginosa the major interest has centered on ceftazidime .
C0007554
cefotaxime
C0007561
ceftriaxone